Evidence map›Paper›PMID 33020165›Full record

ArticleAntimicrobial agents and chemotherapy2020

Emily R Bowman, Cheryl Cameron, Brian Richardson, Manjusha Kulkarni, Janelle Gabriel, Aaren Kettelhut, Lane Hornsby, Jesse J Kwiek, Abigail Norris Turner, Carlos Malvestutto and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Emily R BowmanThe Ohio State University, Columbus, Ohio, USA Emily.Bowman@osumc.edu.ORCID 0000-0003-1783-0361
Cheryl CameronCase Western Reserve University, Cleveland, Ohio, USA.
Brian RichardsonCase Western Reserve University, Cleveland, Ohio, USA.
Manjusha KulkarniThe Ohio State University, Columbus, Ohio, USA.
Janelle GabrielThe Ohio State University, Columbus, Ohio, USA.
Aaren KettelhutThe Ohio State University, Columbus, Ohio, USA.
Lane HornsbyThe Ohio State University, Columbus, Ohio, USA.
Jesse J KwiekThe Ohio State University, Columbus, Ohio, USA.
Abigail Norris TurnerThe Ohio State University, Columbus, Ohio, USA.
Carlos MalvestuttoThe Ohio State University, Columbus, Ohio, USA.
Jose BazanThe Ohio State University, Columbus, Ohio, USA.
Susan L KoletarThe Ohio State University, Columbus, Ohio, USA.
Susanne Doblecki-LewisUniversity of Miami, Miami, Florida, USA.
Michael M LedermanCase Western Reserve University, Cleveland, Ohio, USA.
Mark CameronCase Western Reserve University, Cleveland, Ohio, USA.
Nichole R KlattDepartment of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Jordan E LakeThe University of Texas Health Science Center, Houston, Texas, USA.
Nicholas T FunderburgThe Ohio State University, Columbus, Ohio, USA.
The Ohio State University · USCase Western Reserve University · USThe University of Texas Health Science Center at Houston · USUniversity of Miami · USUniversity of Minnesota · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Cellular mediators of vascular inflammation in treated HIV-infectionR01HL134544 · NHLBI · OHIO STATE UNIVERSITY · PI FUNDERBURG, NICHOLAS T. · 2016 to 2019
$3.2M
NCATS NIH HHS UL1 TR002733NCI NIH HHS P30 CA016058NHLBI NIH HHS R01 HL134544
6 · The paper itself

Abstract

The use of antiretroviral therapy (ART) as preexposure prophylaxis (PrEP) is an effective strategy for preventing HIV acquisition. The cellular consequences of PrEP exposure, however, have not been sufficiently explored to determine potential effects on health in individuals without HIV. In this study, peripheral blood mononuclear cells (PBMCs) from people without HIV were exposed to tenofovir disoproxil fumarate (TDF) or emtricitabine (FTC) overnight. Mitochondrial mass and function were measured by flow cytometry and an Agilent XFp analyzer. Monocyte-derived macrophages (MDMs) were differentiated in 20% autologous serum for 5 days in the presence or absence of TDF or FTC, and surface markers, lipid uptake, and efferocytosis were measured by flow cytometry. MDM gene expression was measured using transcriptome sequencing (RNA-seq). Plasma lipids were measured using mass spectrometry. PBMCs exposed to TDF or FTC had decreased maximal oxygen consumption rate (OCR) and reduced mitochondrial mass. Exposure to PrEP also increased reactive oxygen species (ROS) production from monocyte subsets. Compared to MDMs cultured in medium alone, cells differentiated in the presence of TDF (829 genes) or FTC (888 genes) had significant changes in gene expression. Further, PrEP-exposed MDMs had decreased mitochondrial mass and displayed increased lipid uptake and reduced efferocytosis. Plasma biomarkers and lipid levels were also altered

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisEmtricitabineHumansLeukocytes, MononuclearMitochondriaTranscriptomeAnti-HIV AgentsEmtricitabinehuman immunodeficiency virusinflammationleukocyteslipidsmitochondrial dysfunctionpreexposure prophylaxis

Identifiers

PMID33020165
PMCPMC7927818
OpenAlexW3090171943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.